Loading viewer...
earnings
Format: PDF earnings
Novavax reported Q2 2021 earnings with significant progress on its COVID-19 vaccine candidate NVX-CoV2373, including regulatory filings for EUA and confirmed high efficacy in the PREVENT-19 Phase 3 trial. The company confirmed manufacturing guidance of 100M doses monthly by end of Q3 and 150M doses by end of Q4, and announced new agreements with GAVI and the European Commission to expand global distribution.
investor_presentation
89 Pages
earnings
47 Pages
Adani Green Energy Limited
Grupo Pão de Açúcar 2Q16 Results July 2016
earningsearnings
10 Pages
GPA (Grupo Pão de Açúcar)